Skip to main content

Advertisement

SpringerLink
Log in

Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

AR-C155858 and AZD3965, pyrrole pyrimidine derivatives, represent potent monocarboxylate transporter 1 (MCT1) inhibitors, with potential immunomodulatory and chemotherapeutic properties. Currently, there is limited information on the inhibitory properties of this new class of MCT1 inhibitors. The purpose of this study was to characterize the concentration- and time-dependent inhibition of L-lactate transport and the membrane permeability properties of AR-C155858 and AZD3965 in the murine 4T1 breast tumor cells that express MCT1. Our results demonstrated time-dependent inhibition of L-lactate uptake by AR-C155858 and AZD3965 with maximal inhibition occurring after a 5-min pre-incubation period and prolonged inhibition. Following removal of AR-C155858 or AZD3965 from the incubation buffer, inhibition of L-lactate uptake was only fully reversed after 3 and 12 h, respectively, indicating that these inhibitors are slowly reversible. The uptake of AR-C155858 was concentration-dependent in 4T1 cells, whereas the uptake of AZD3965 exhibited no concentration dependence over the range of concentrations examined. The uptake kinetics of AR-C155858 was best fitted to a Michaelis-Menten equation with a diffusional clearance component, P (Km = 0.399 ± 0.067 μM, Vmax = 4.79 ± 0.58 pmol/mg/min, and P = 0.330 ± 0.088 μL/mg/min). AR-C155858 uptake, but not AZD3965 uptake, was significantly inhibited by alpha-cyano-4-hydroxycinnamic acid, a known nonspecific inhibitor of MCTs 1, 2, and 4. AR-C155858 demonstrated a trend toward higher uptake at lower pH, a characteristic of proton-dependent MCT1. These findings provide evidence that AR-C155858 and AZD3965 exert slowly reversible inhibition of MCT1-mediated L-lactate uptake in 4T1 cells, with AR-C155858 representing a potential substrate of MCT1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

MCTs:

Monocarboxylate transporters

CHC:

Alpha-cyano-4-hydroxycinnamic acid

References

  1. Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008;10(2):311–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv. 2004;447(5):619–28.

    CAS  PubMed  Google Scholar 

  3. Halestrap AP. The monocarboxylate transporter family--structure and functional characterization. IUBMB Life. 2012;64(1):1–9.

    CAS  Google Scholar 

  4. Halestrap AP, Wilson MC. The monocarboxylate transporter family--role and regulation. IUBMB Life. 2012;64(2):109–19.

    CAS  PubMed  Google Scholar 

  5. Fishbein WN, Merezhinskaya N, Foellmer JW. Relative distribution of three major lactate transporters in frozen human tissues and their localization in unfixed skeletal muscle. Muscle Nerve. 2002;26(1):101–12.

    CAS  PubMed  Google Scholar 

  6. Juel C, Halestrap AP. Lactate transport in skeletal muscle - role and regulation of the monocarboxylate transporter. J Physiol. 1999;517(Pt 3):633–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW. Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J. 1999;341(Pt 3):529–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000;350(Pt 1):219–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Manning Fox JE, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol. 2000;529(Pt 2):285–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queiros O, Preto A, et al. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol. 2014;29(12):1511–24.

    CAS  PubMed  Google Scholar 

  11. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr. 2012;44(1):127–39.

    CAS  PubMed  Google Scholar 

  12. Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech. 2011;4(6):727–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol. 2010;6(1):127–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol. 2010;2010:427694.

    PubMed  PubMed Central  Google Scholar 

  15. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, et al. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol. 2011;26(10):1279–86.

    CAS  PubMed  Google Scholar 

  16. Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, et al. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology. 2010;56(7):860–7.

    Google Scholar 

  17. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. The J Biol Chem 2006;281(14):9030–9037.

  18. Rosafio K, Pellerin L. Oxygen tension controls the expression of the monocarboxylate transporter MCT4 in cultured mouse cortical astrocytes via a hypoxia-inducible factor-1alpha-mediated transcriptional regulation. Glia. 2014;62(3):477–90.

    PubMed  Google Scholar 

  19. Lim KS, Lim KJ, Price AC, Orr BA, Eberhart CG, Bar EE. Inhibition of monocarboxylate transporter-4 depletes stem-like glioblastoma cells and inhibits HIF transcriptional response in a lactate-independent manner. Oncogene. 2014;33(35):4433–41.

    CAS  PubMed  Google Scholar 

  20. Hamdan L, Arrar Z, Al Muataz Y, Suleiman L, Negrier C, Mulengi JK, et al. Alpha cyano-4-hydroxy-3-methoxycinnamic acid inhibits proliferation and induces apoptosis in human breast cancer cells. PLoS One. 2013;8(9):e72953.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102(7):1247–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Polanski R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014;20(4):926–37.

    CAS  PubMed  Google Scholar 

  23. Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014;13(12):2805–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Morais-Santos F, Granja S, Miranda-Goncalves V, Moreira AH, Queiros S, Vilaca JL, et al. Targeting lactate transport suppresses in vivo breast tumour growth. Oncotarget. 2015;6(22):19177–89.

    PubMed  PubMed Central  Google Scholar 

  25. Kong SC, Nohr-Nielsen A, Zeeberg K, Reshkin SJ, Hoffmann EK, Novak I, et al. Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas. 2016;45(7):1036–47.

    CAS  PubMed  Google Scholar 

  26. Meredith D, Christian HC. The SLC16 monocaboxylate transporter family. Xenobiotica; the fate of foreign compounds in biological systems 2008;38(7–8):1072–106.

  27. Guile SD, Bantick JR, Cheshire DR, Cooper ME, Davis AM, Donald DK, et al. Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds. Bioorg Med Chem Lett. 2006;16(8):2260–5.

    CAS  PubMed  Google Scholar 

  28. Pahlman C, Qi Z, Murray CM, Ferguson D, Bundick RV, Donald DK, et al. Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT-1. Transpl Intern. 2013;26(1):22–9.

    Google Scholar 

  29. Bueno V, Binet I, Steger U, Bundick R, Ferguson D, Murray C, et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation. 2007;84(9):1204–7.

    CAS  PubMed  Google Scholar 

  30. Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010;425(3):523–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Ovens MJ, Manoharan C, Wilson MC, Murray CM, Halestrap AP. The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein. Biochem J. 2010;431(2):217–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 2011;102(5):1007–13.

    CAS  PubMed  Google Scholar 

  33. Wang H, Yang C, Doherty JR, Roush WR, Cleveland JL, Bannister TD. Synthesis and structure-activity relationships of pteridine dione and trione monocarboxylate transporter 1 inhibitors. J Med Chem. 2014;57(17):7317–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Vijay N, Morse BL, Morris ME. A novel Monocarboxylate transporter inhibitor as a potential treatment strategy for gamma-Hydroxybutyric acid overdose. Pharm Res. 2015;32(6):1894–906.

    CAS  PubMed  Google Scholar 

  35. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J. 1999;343(Pt 2):281–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Guan X, Bryniarski MA, Morris ME. In vitro and in vivo efficacy of the Monocarboxylate transporter 1 inhibitor AR-C155858 in the murine 4T1 breast Cancer tumor model. AAPS J. 2018;21(1):3.

    PubMed  Google Scholar 

  37. Nancolas B, Sessions RB, Halestrap AP. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity. Biochem J. 2015;466(1):177–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Guan X, Ruszaj D, Morris ME. Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: application to pharmacokinetic and breast tumor xenograft studies. J Pharm Biomed Anal. 2018;155:270–5.

    CAS  PubMed  Google Scholar 

  39. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 1985;45(9):4091–6.

    CAS  PubMed  Google Scholar 

  40. Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. Oncotarget. 2017;8(41):69219–36.

    PubMed  PubMed Central  Google Scholar 

  41. Sarah ER, Halford PJ, Steve W, Hirschberg S, Katugampola S, Veal G, et al. A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours. American Society of Clinical Oncology Annual Meeting; Monday, June 5, 20172017.

  42. Dienel GA. Brain lactate metabolism: the discoveries and the controversies. J Cerebral Blood Flow Metab. 2012;32(7):1107–38.

    CAS  Google Scholar 

  43. Colen CB, Seraji-Bozorgzad N, Marples B, Galloway MP, Sloan AE, Mathupala SP. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery. 2006;59(6):1313–23 discussion 23-4.

    PubMed  PubMed Central  Google Scholar 

  44. Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia. 2011;13(7):620–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118(12):3930–42.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Authorship Contributions

Participated in research design: X.G. and M.E.M.

Conducted experiments: X.G. and V.R.

Contributed new reagents or analytic tools: X.G. and M.E.M.

Performed data analysis: X.G. and M.E.M.

Wrote or contributed to the writing of the manuscript: X.G. and M.E.M.

Funding

This work was funded by the National Institute of Health National Institute on Drug Abuse (grant DA023223). X.G. was funded in part by an Allen Barnett Fellowship.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 352 Kapoor Hall, Buffalo, NY, 14214, USA

    Xiaowen Guan, Vivian Rodriguez-Cruz & Marilyn E. Morris

Authors
  1. Xiaowen Guan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vivian Rodriguez-Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marilyn E. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marilyn E. Morris.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guan, X., Rodriguez-Cruz, V. & Morris, M.E. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells. AAPS J 21, 13 (2019). https://doi.org/10.1208/s12248-018-0279-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-018-0279-5

KEY WORDS

Search

Navigation